Avidity Biosciences (RNA) Projected to Announce Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($1.4175) per share and revenue of $0.6670 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.08. The company had revenue of $19.64 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, analysts expect Avidity Biosciences to post $-6 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Avidity Biosciences Price Performance

NASDAQ RNA opened at $12.24 on Tuesday. The company has a market cap of $209.43 million and a price-to-earnings ratio of -12.62. The stock’s fifty day moving average price is $12.35 and its 200 day moving average price is $24.41. Avidity Biosciences has a 1 year low of $11.13 and a 1 year high of $16.77.

Hedge Funds Weigh In On Avidity Biosciences

A number of hedge funds have recently made changes to their positions in RNA. EFG International AG acquired a new stake in shares of Avidity Biosciences in the fourth quarter worth approximately $33,000. Los Angeles Capital Management LLC acquired a new position in Avidity Biosciences in the 4th quarter valued at $34,000. Smartleaf Asset Management LLC raised its stake in Avidity Biosciences by 426.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 397 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Avidity Biosciences by 1,659.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,543 shares in the last quarter. Finally, Comerica Bank lifted its holdings in Avidity Biosciences by 75.9% in the 3rd quarter. Comerica Bank now owns 1,335 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 576 shares in the last quarter.

Analyst Ratings Changes

RNA has been the subject of a number of research reports. HC Wainwright started coverage on Avidity Biosciences in a report on Thursday, August 6th. They set a “buy” rating and a $25.00 target price for the company. Wall Street Zen upgraded shares of Avidity Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, May 30th. Weiss Ratings raised shares of Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Leerink Partners began coverage on shares of Avidity Biosciences in a research note on Friday, May 15th. They set an “outperform” rating for the company. Finally, Zacks Research raised shares of Avidity Biosciences to a “hold” rating in a report on Friday, June 19th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $63.85.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.